Targeting CerS6-dependent ceramide synthesis in the hypothalamus holds promise for obesity and diabetes therapies, offering potential advantages over complete inhibition of sphingolipid/ceramide synthesis with reduced side effects. This evidence concerns the gene CERS6 and diabetes mellitus.